| Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype Ü Yasar, C Forslund‐Bergengren, G Tybring, P Dorado, A LLerena, ... Clinical Pharmacology & Therapeutics 71 (1), 89-98, 2002 | 282 | 2002 |
| CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers P Dorado, R Berecz, MJ Norberto, Ü Yasar, ML Dahl, A LLerena European journal of clinical pharmacology 59, 221-225, 2003 | 131 | 2003 |
| QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations A Llerena, R Berecz, P Dorado, A De la Rubia Journal of psychopharmacology 18 (2), 189-193, 2004 | 108 | 2004 |
| Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions A LLerena, P Dorado, R Berecz, AP González, EM Peñas-LLedó European journal of clinical pharmacology 59, 869-873, 2004 | 101 | 2004 |
| Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use P Dorado, MC Cáceres, E Pozo-Guisado, ML Wong, J Licinio, A LLerena Biotechniques 39 (4S), S571-S574, 2005 | 98 | 2005 |
| CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans A Llerena, P Dorado, R Ramírez, I González, M Alvarez, EM Peñas-Lledó, ... The pharmacogenomics journal 12 (2), 176-183, 2012 | 97 | 2012 |
| Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity A LLerena, P Dorado, EM Peñas-Lledó Future Medicine Ltd 10 (1), 17-28, 2009 | 93 | 2009 |
| Lower frequency of CYP2C9* 2 in Mexican-Americans compared to Spaniards A Llerena, P Dorado, F O'kirwan, R Jepson, J Licinio, ML Wong The Pharmacogenomics Journal 4 (6), 403-406, 2004 | 91 | 2004 |
| Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers I González, EM Peñas-Lledó, B Pérez, P Dorado, M Álvarez, A LLerena Future Medicine Ltd 9 (7), 833-840, 2008 | 89 | 2008 |
| The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions R Berecz, P Dorado, ADL Rubia, MC Caceres, I Degrell, A LLerena Current drug targets 5 (6), 573-579, 2004 | 77 | 2004 |
| CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits P Dorado, EM Penas-LLedo, A LLerena Pharmacogenomics 8 (11), 1597-1608, 2007 | 75 | 2007 |
| QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients A LLerena, R Berecz, A de la Rubia, P Dorado Journal of psychopharmacology 16 (4), 361-364, 2002 | 73 | 2002 |
| Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients A LLerena, P Dorado, R Berecz, A González, MJ Norberto, A de la Rubia, ... Journal of Chromatography B 783 (1), 25-31, 2003 | 70 | 2003 |
| Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype R Berecz, A de la Rubia, P Dorado, P Fernández-Salguero, ML Dahl, ... European journal of clinical pharmacology 59, 45-50, 2003 | 68 | 2003 |
| CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards P Dorado, MG Sosa-Macias, EM Peñas-Lledó, RE Alanis-Bañuelos, ... The pharmacogenomics journal 11 (2), 108-112, 2011 | 66 | 2011 |
| Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers EM Peñas-LLedó, P Dorado, R Pacheco, I Gonzalez, A LLerena Pharmacogenomics 10 (7), 1111-1120, 2009 | 64 | 2009 |
| Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions A LLerena, R Berecz, P Dorado, CS de la Garza, MJ Norberto, M Cáceres, ... Journal of Chromatography B 783 (1), 213-219, 2003 | 60 | 2003 |
| Low frequency of CYP2D6 poor metabolizers among schizophrenia patients A Llerena, P Dorado, EM Peñas-Lledó, MC Cáceres, A De la Rubia The pharmacogenomics journal 7 (6), 408-410, 2007 | 58 | 2007 |
| High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders EM Peñas-Lledó, P Dorado, Z Agüera, M Gratacós, X Estivill, ... Mol Psychiatry 16 (7), 691-2, 2011 | 56 | 2011 |
| Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes A LLerena, R Berecz, A de la Rubia, P Fernández-Salguero, P Dorado Therapeutic drug monitoring 23 (6), 616-620, 2001 | 56 | 2001 |
Adrián LLerena MD PhD Professor Cli...INUBE Biosanitary University Research Institute. University of Extremadura. CICAB Clinical Research在 unex.es 的电子邮件经过验证
